Roche said new phase 3 data for divarasib support a potency and selectivity advantage versus first-generation KRAS G12C inhibitors, including competitor regimens from Amgen and Bristol Myers Squibb. The company plans to submit the phase 3 results to regulators for potential use in non-small cell lung cancer driven by KRAS G12C. If reviewed favorably, the update could reshape competition in KRAS G12C—one of the most crowded molecularly targeted oncology categories—by strengthening Roche’s positioning with a next-generation inhibitor plan.